Tesamorelin: The GHRH Peptide With Real FDA Approval and Real Trials

What is tesamorelin?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary to secrete growth hormone. It is a 44-amino-acid peptide built on the natural GRF(1-44) sequence, with a chemical group added to the N-terminus so that it survives longer in the bloodstream before enzymes break it down. It is sold under the brand name Egrifta and was developed by the Canadian company Theratechnologies.

That one modification is the whole point. Native GHRH is destroyed within minutes by the enzyme dipeptidyl peptidase-4, which is why the natural hormone is useless as a drug. Attaching a stabilizing group lets tesamorelin keep binding the GHRH receptor long enough to produce a clinically meaningful rise in growth hormone. In that sense it belongs to the same family as sermorelin and CJC-1295 — GHRH-based molecules that stimulate the pituitary rather than replacing growth hormone directly — but it is the one that was carried all the way through phase 3 trials and licensed as a real drug.

The reason it exists is specific. People living with HIV who have been on antiretroviral therapy for years can develop a fat-redistribution syndrome, sometimes called lipodystrophy, in which fat is lost from the limbs and face and accumulates deep in the abdomen as visceral adipose tissue. That visceral fat is metabolically active and associated with cardiovascular and metabolic risk. Tesamorelin was designed and approved to shrink it. A 2011 review in HIV/AIDS lays out how the drug fits into the management of HIV-associated lipodystrophy.

How does tesamorelin work?

Tesamorelin works one step upstream of growth hormone itself. It binds the GHRH receptor on the somatotroph cells of the anterior pituitary and prompts them to release the body's own growth hormone in a pattern that still resembles natural pulses. Circulating growth hormone then acts on the liver and other tissues to raise insulin-like growth factor 1 (IGF-1), and growth hormone's direct lipolytic effect drives the breakdown of stored fat.

Two features explain why the fat loss lands where it does. First, visceral fat is unusually sensitive to growth hormone's lipolytic signaling, so raising growth hormone tends to strip visceral fat preferentially over subcutaneous fat. Second, because tesamorelin nudges the pituitary rather than flooding the body with external growth hormone, IGF-1 feedback still operates — the system retains some of its own regulation, which is part of the rationale for using a secretagogue instead of recombinant growth hormone. A broader look at how this class behaves is covered in a 2019 review of growth hormone secretagogues in the modern clinic, and the underlying biology of peptide hormones is summarized in this overview of precursor proteins and biological function.

The measurable fingerprint of this mechanism showed up clearly in trials: IGF-1 rose by roughly 80% on tesamorelin, confirming the drug did what it was designed to do at the level of the GH axis. That IGF-1 rise is also the source of its main long-term safety question, discussed below.

Is tesamorelin FDA approved?

Yes — and this is the single fact that separates tesamorelin from almost every other peptide sold online. The FDA approved tesamorelin in November 2010 under the brand Egrifta, for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It went through the standard drug-development pathway of adequately powered, randomized, placebo-controlled trials — the framework outlined in these primers on drug development and clinical trial phases.

The product has been reformulated over time. The original daily formulation gave way to Egrifta SV, and in 2025 the FDA approved Egrifta WR (the "F8" formulation), which is more stable and simpler to prepare and is the version dispensed today. Across all of these, the approved indication has never widened. It remains, word for word, excess abdominal fat in HIV-associated lipodystrophy.

What approval does not mean is worth stating plainly, because the marketing around this peptide blurs it constantly. FDA approval of tesamorelin does not make it a general obesity drug, a bodybuilding aid, or an anti-aging treatment. Those uses are unapproved. The evidence that earned the approval was generated in a very particular population, and a regulator's sign-off is bounded by the population and endpoint that were actually studied.

Does tesamorelin actually work?

For its approved purpose, the answer is a clear yes — which, again, is unusual in this corner of the peptide world.

The pivotal evidence is a 2007 trial published in the New England Journal of Medicine. Researchers randomly assigned 412 people with HIV and excess abdominal fat to daily subcutaneous tesamorelin or placebo for 26 weeks. Visceral adipose tissue, measured by CT, fell 15.2% in the tesamorelin group and rose 5.0% in the placebo group; triglycerides and the total-to-HDL cholesterol ratio improved; and IGF-1 climbed 81%. A second phase 3 trial of similar design reproduced the visceral-fat effect, and a 2010 pooled analysis of both trials confirmed a visceral-fat reduction in the mid-to-high teens by percentage, holding up across the combined population.

The most important detail is what did not change. Subcutaneous fat stayed essentially flat, and total body weight moved very little. Tesamorelin did not make people uniformly smaller; it selectively pulled down the deep visceral compartment. That selectivity is exactly what the drug was designed to do, and it is the reason its trials used CT-measured visceral fat as the endpoint rather than the bathroom scale.

Tesamorelin and liver fat: what the studies found

The visceral-fat story has a second act in the liver, and it is arguably the more scientifically interesting one. Because visceral adiposity and fatty liver travel together, researchers asked whether tesamorelin's action on visceral fat would also reduce fat inside the liver.

A 2014 randomized clinical trial in JAMA answered the first version of that question. In people with HIV and abdominal fat accumulation, tesamorelin produced a reduction in liver fat alongside visceral fat, measured by magnetic resonance spectroscopy, with a relative decrease in hepatic fat on the order of a third versus placebo. A 2019 trial in The Lancet HIV went further, enrolling people with HIV who specifically had non-alcoholic fatty liver disease and treating them for a full year. Tesamorelin lowered hepatic fat and reduced progression of liver fibrosis compared with placebo — a harder, more meaningful endpoint than fat content alone.

These are genuinely strong findings for a peptide, and they are why tesamorelin gets cited in metabolic-health discussions far beyond HIV medicine. The honest caveat is the same one that runs through the whole drug: this was all studied in people with HIV. There is no equivalent randomized trial of tesamorelin for fatty liver disease in the general population, so extending the liver-fat result to a non-HIV person with metabolic fatty liver is an extrapolation, not a proven use.

Why is tesamorelin's approval so narrow?

If tesamorelin reliably shrinks visceral fat and improves liver fat, why is it approved only for a few hundred thousand people with HIV rather than for the millions with abdominal obesity? Three reasons.

• It was only ever tested there. Approval follows the evidence, and every phase 3 tesamorelin trial enrolled people with HIV-associated fat accumulation. A drug is licensed for the population in which it was proven, full stop. No large trial has tested tesamorelin for common obesity or general metabolic disease.
• The effect is not durable. The pooled phase 3 data showed that when people stopped tesamorelin, visceral fat re-accumulated. The drug suppresses the fat redistribution while it is being taken rather than resetting it, which frames it as ongoing therapy for a chronic problem, not a course you complete.
• Raising growth hormone has real trade-offs. Growth hormone is diabetogenic — it can worsen glucose control — and chronic IGF-1 elevation carries theoretical long-term risk. In a population that needs visceral-fat reduction for a specific medical reason, that trade-off can be justified and monitored. As a lifestyle drug for otherwise healthy people, the risk-benefit math is entirely different and untested.

Put simply, the narrow label is not an oversight waiting to be corrected. It is an accurate reflection of where the evidence ends. If you are interested in fat loss more broadly, the drugs with population-scale obesity trials are the GLP-1 receptor agonists and newer dual and triple agonists, not GH-axis peptides — a distinction we cover in the guide to peptides for weight loss.

Tesamorelin side effects reported in trials

Because tesamorelin has been through controlled trials and years of post-marketing use, its side-effect profile is genuinely documented rather than anecdotal — another sharp contrast with most peptides. The most common adverse events in trials were:

• Injection-site reactions — redness, itching, pain, or irritation where the drug is given, the single most frequently reported effect.
• Joint and muscle pain — arthralgia and myalgia, familiar effects of raising growth hormone.
• Fluid retention — peripheral edema and a puffy, swollen sensation, again a classic growth-hormone effect.
• Glucose intolerance and higher blood sugar — growth hormone opposes insulin, so blood glucose can drift up, which matters most in people who already have or are at risk of diabetes.
• Raised IGF-1 — expected from the mechanism, but the label directs clinicians to monitor IGF-1 and to consider stopping if it stays persistently high, because the effects of long-term IGF-1 elevation are not fully known.

Most reported events were mild, but tesamorelin also carries firm contraindications that reflect the seriousness of manipulating the GH axis. It is not to be used in people with active malignancy, because IGF-1 can theoretically promote tumor growth; in people with disruption of the hypothalamic-pituitary axis, such as a pituitary tumor, pituitary surgery, head radiation, or head trauma; or in pregnancy, where animal data raised developmental concerns and the drug offers no benefit. Hypersensitivity to the drug is also a contraindication. These are label-level restrictions, not internet cautions — one more sign of how much more is known about this molecule than about its unapproved cousins.

Tesamorelin vs sermorelin, ipamorelin and CJC-1295

The GH-axis peptides get lumped together in marketing as interchangeable ways to "boost your growth hormone naturally." Their mechanisms overlap, but their evidence bases could hardly be more different, and that is the comparison that actually matters.

Sermorelin is the closest cousin: a truncated GHRH(1-29) peptide that was actually FDA-approved as Geref, used both to treat and to diagnose growth hormone deficiency in children and studied as once-daily therapy in GH-deficient children. But Geref was withdrawn from the US market for commercial reasons, so today sermorelin reaches patients only through compounding pharmacies, not as an approved product. CJC-1295 is a long-acting GHRH analog with only small early-phase human pharmacology behind it, and ipamorelin works through a different door entirely — it is a selective ghrelin-receptor secretagogue, not a GHRH analog, with no approved use in people. Tesamorelin is the only member of this group that a regulator has ever cleared as a marketed drug based on large randomized trials.

Is tesamorelin a weight-loss drug?

Not in any ordinary sense, and treating it like one misunderstands what the trials showed. Tesamorelin redistributes fat; it does not produce the large drops in total body weight that people mean by "weight loss." In the pivotal trials, participants lost visceral fat while total weight and subcutaneous fat barely moved. Someone hoping to see a smaller number on the scale would likely be disappointed, because the change is internal — deep abdominal fat coming down without a dramatic shift in overall body mass.

There is also no trial of tesamorelin for obesity in the general population. Every efficacy dataset comes from people with HIV-associated fat accumulation. So the honest framing is that tesamorelin is a targeted visceral-fat therapy for a specific condition, not a general obesity treatment. When the goal is meaningful reduction in body weight, the drugs with directly relevant, population-scale evidence are the incretin-based agents — GLP-1 agonists and the newer combinations — rather than any GH-axis peptide. Whatever the tool, the value of a consistent record of doses, weight and side effects over time is the same, which is the case for structured tracking made throughout this hub.

Is tesamorelin legal to buy?

Tesamorelin is a prescription drug within its approved indication, which means the legal, regulated way to obtain it is a prescription for HIV-associated lipodystrophy filled through a licensed pharmacy as Egrifta WR. Prescribing an approved drug off-label is something clinicians can do at their discretion, but that is a clinical decision made with a licensed prescriber, not an over-the-counter purchase.

Most tesamorelin sold online is a different animal entirely: unregulated "research chemical" vials labeled not for human consumption, sold by vendors with no oversight of identity, purity, or sterility. That labeling is a legal shield for the seller, not a quality guarantee, and buying a prescription peptide this way sidesteps the entire framework that makes the approved product safe to use. The general rules for how these categories work are covered in are peptides legal?

Two more points close the loop. Tesamorelin raises growth hormone and IGF-1, so it is prohibited in sport under anti-doping rules — an athlete using it, approved or not, risks a violation. And if a clinician does decide it is appropriate for you, absorption and local tolerability still depend on technique and site, which is why our overview of subcutaneous injection sites and rotation is worth reading alongside this page.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed, or to the FDA's approval and labeling for Egrifta:

1. Metabolic effects of a growth hormone-releasing factor in patients with HIV — PubMed 18057338
2. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation — PubMed 20554713
3. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation — PubMed 25038357
4. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial — PubMed 31611038
5. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy — PubMed 22096409
6. The role of growth hormone secretagogues in the modern clinic — PubMed 32257855
7. Sermorelin: a review of its use in the diagnosis and treatment of children with growth hormone deficiency — PubMed 18031173
8. Once daily subcutaneous growth hormone-releasing hormone therapy in GH-deficient children — PubMed 8772599
9. Ipamorelin, the first selective growth hormone secretagogue — PubMed 9849822
10. Understanding peptide hormones: from precursor proteins to biological function — PubMed 40234176
11. Drug Development 101: A Primer — PubMed 32762387
12. Drug Trials (overview of clinical trial phases) — PubMed 31536202

Regulatory reference: the FDA's approved Egrifta prescribing information, including the approved HIV-lipodystrophy indication, contraindications, and IGF-1 monitoring guidance, and the 2025 approval of the Egrifta WR formulation.

Keep reading